COMBIPRES
Clinical safety rating: caution
Comprehensive clinical and safety monograph for COMBIPRES (COMBIPRES).
Combipres is a fixed-dose combination of clonidine (alpha-2 adrenergic agonist) and chlorthalidone (thiazide-like diuretic). Clonidine stimulates alpha-2 receptors in the brainstem, reducing sympathetic outflow, leading to decreased peripheral vascular resistance, heart rate, and blood pressure. Chlorthalidone inhibits the sodium-chloride symporter in the distal convoluted tubule of the kidney, increasing sodium, chloride, and water excretion, reducing plasma volume and blood pressure.
| Metabolism | Clonidine is metabolized by the liver via cytochrome P450 enzymes, primarily CYP2D6, to inactive metabolites. Chlorthalidone is metabolized minimally; it is excreted largely unchanged in urine. |
| Excretion | Renal: clonidine 40-60% unchanged, chlorthalidone 50-70% unchanged; biliary/fecal: clonidine ~20% as metabolites, chlorthalidone minimal. |
| Half-life | Clonidine: 6-20 hours (mean 12 h) prolonged in renal impairment; chlorthalidone: 40-60 hours (mean 50 h) allowing alternate-day dosing. |
| Protein binding | Clonidine: 20-40% (albumin); chlorthalidone: 75% (albumin and erythrocytes). |
| Volume of Distribution | Clonidine: 2-3 L/kg (extensive tissue distribution); chlorthalidone: 3-4 L/kg (large Vd due to erythrocyte binding). |
| Bioavailability | Oral: clonidine 75-95% (immediate release), chlorthalidone ~65%. |
| Onset of Action | Oral: clonidine 30-60 min, chlorthalidone 2 hours; maximal effect clonidine 2-4 h, chlorthalidone 4-6 h. |
| Duration of Action | Clonidine: 6-12 hours (dose-dependent); chlorthalidone: 24-72 hours (enables once-daily dosing). |
| Molecular Weight | Clonidine: 230.09 Da; Chlorthalidone: 338.76 Da |
1-2 tablets orally twice daily. Each tablet contains clonidine 0.1 mg and chlorthalidone 15 mg.
| Dosage form | TABLET |
| Renal impairment | Contraindicated for GFR <30 mL/min. For GFR 30-50 mL/min, reduce dose by 50% starting with 1 tablet daily. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25-50%. Child-Pugh C: not recommended. |
| Pediatric use | Not recommended for use in pediatric patients due to lack of safety and efficacy data. |
| Geriatric use | Initiate with 1 tablet daily; monitor for orthostatic hypotension and electrolyte imbalance. Avoid in frail elderly. |
| 1st trimester | Avoid; associated with fetal abnormalities including oligohydramnios and neonatal hypotension. |
| 2nd trimester | Avoid; risk of oligohydramnios and fetal renal dysfunction. |
| 3rd trimester | Avoid; may cause neonatal hypotension, hyperkalemia, and renal failure. |
Clinical note
Comprehensive clinical and safety monograph for COMBIPRES (COMBIPRES).
| Placental transfer | Both clonidine and chlorthalidone cross the placenta; clonidine achieves fetal concentrations approximately equal to maternal levels. |
| Breastfeeding | Clonidine is excreted into breast milk with infant doses up to 20% of maternal weight-adjusted dose; chlorthalidone is excreted in low amounts. Monitor infant for hypotension, drowsiness, and electrolyte disturbances. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to clonidine or chlorthalidone or any componentAnuriaHepatic coma or pre-comaSulfonamide allergy (chlorthalidone is a sulfonamide derivative)
| Precautions | Rebound hypertension on abrupt discontinuation (clonidine component) – taper slowly., Orthostatic hypotension, especially with chlorthalidone., Electrolyte imbalances including hypokalemia, hyponatremia, and hypomagnesemia (chlorthalidone)., Renal impairment – monitor renal function., Hepatic impairment – use with caution., May cause drowsiness or dizziness – caution when driving or operating machinery. |
| Food/Dietary | Avoid high-sodium foods as they can counteract antihypertensive effects. Grapefruit juice may enhance clonidine absorption; limit consumption. Alcohol may potentiate orthostatic hypotension and sedation. Foods high in potassium (e.g., bananas, oranges, spinach) should be consumed in moderation as chlorthalidone can cause hypokalemia; monitor potassium levels. Caffeine may reduce clonidine efficacy; avoid excessive intake. |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | COMBIPRES contains reserpine and hydrochlorothiazide. Reserpine: Crosses placenta; associated with increased risk of fetal respiratory depression, bradycardia, and hypothermia in neonates if used near term. Hydrochlorothiazide: Use in pregnancy may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances. Avoid in first trimester due to potential teratogenicity (neural tube defects and cardiovascular anomalies reported). Second and third trimester: Use only if clearly needed; may cause fetal and neonatal electrolyte disturbances. |
| Fetal Monitoring | Monitor maternal blood pressure, serum electrolytes (especially potassium and sodium), renal function, and fetal growth and well-being via ultrasound. Neonates should be monitored for bradycardia, respiratory depression, hypothermia, and electrolyte disturbances. |
| Fertility Effects | Reserpine may cause decreased libido and impaired sexual function in both sexes. Hydrochlorothiazide has no known direct effects on fertility. Overall, COMBIPRES may impair fertility via reserpine's effects on reproductive function. |
| Clinical Pearls | Combipres is a fixed-dose combination of clonidine and chlorthalidone. Clonidine may cause rebound hypertension upon abrupt discontinuation; taper over 2-4 days. Chlorthalidone can cause electrolyte imbalances; monitor potassium and magnesium. Use cautiously in patients with renal impairment (CrCl <30 mL/min) or severe coronary insufficiency. Avoid in patients with history of angioedema from thiazides. Orthostatic hypotension is common; advise rising slowly. |
| Patient Advice | Take exactly as prescribed; do not stop suddenly without doctor's advice as this can cause dangerous rises in blood pressure. · If you miss a dose, take it as soon as remembered unless near next dose; do not double dose. · This medication may cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you. · Rise slowly from sitting or lying positions to prevent fainting. · Report symptoms of electrolyte imbalance such as muscle cramps, weakness, irregular heartbeat, or excessive thirst. · Avoid alcohol as it can increase side effects like dizziness and drowsiness. · Inform your doctor if you develop severe diarrhea or vomiting, as it may affect drug absorption. · Do not take other blood pressure medications or supplements without medical advice. · Store at room temperature away from moisture and heat. |